Journal
EXPERT REVIEW OF VACCINES
Volume 13, Issue 4, Pages 507-519Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2014.890053
Keywords
alginate; Th17; vaccine; Pseudomonas aeruginosa; lipopolysaccharide; flagella; neutrophil
Categories
Funding
- NIH
- Cystic Fibrosis Foundation
- William F. Milton Fund of Harvard Medical School
Ask authors/readers for more resources
Despite the recognition of Pseudomonas aeruginosa as an opportunistic pathogen, no vaccine against this bacteria has come to market. This review describes the current state-of-the-art in vaccinology for this bacterium. This includes a discussion of those at risk for infection, the types of vaccines and the approaches for empirical and targeted antigen selection under development, as well as a perspective on where the field should go. In addition, the challenges in developing a vaccine for those individuals at risk are discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available